Citadel Advisors
XLO icon

Citadel Advisors’s Xilio Therapeutics XLO Stock Holding History

Citadel Advisors’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-31,158
Closed -$279K – 14389
2025
Q4 		$279K Buy
+31,158
New +$327K ﹤0.01% 10301
2025
Q1 		– Sell
-2,880
Closed -$38.5K – 15715
2024
Q4 		$38.5K Buy
+2,880
New +$39.6K ﹤0.01% 12646
2024
Q1 		– Sell
-3,673
Closed -$28.3K – 15536
2023
Q4 		$28.3K Buy
+3,673
New +$72.6K ﹤0.01% 12311
2023
Q3 		– Sell
-939
Closed -$34.5K – 15238
2023
Q2 		$34.5K Sell
939
-4,178
-82% -$178K ﹤0.01% 12217
2023
Q1 		$228K Buy
+5,117
New +$225K ﹤0.01% 9945

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors's XLO Position: Q1 2026 in Review

Citadel Advisors sold out of Xilio Therapeutics (XLO) in Q1 2026, closing a stake of 31,158 shares — an estimated $279K sold.

Citadel Advisors first reported a position in XLO in Q1 2023 and held it in 5 quarters. The position peaked at $279K in Q4 2025. 24 funds tracked by Wall St. Rank hold XLO as of Q1 2026.

  • Citadel Advisors reported no remaining Xilio Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 31,158 Xilio Therapeutics shares in Q1 2026, an estimated $279K.
  • Citadel Advisors first reported a position in Xilio Therapeutics in Q1 2023 and held it in 5 quarters.
  • Citadel Advisors's Xilio Therapeutics position peaked at $279K in Q4 2025.
  • 24 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.